Drug Trial Radar · NCT01137682
Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
Last checked: Nov 20, 2026Latest source record: Apr 5, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
198
Actual
Start
Jul 19, 2010
Primary completion
Jan 22, 2013
Study completion Feb 28, 2017
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 4, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.
Conditions
- Acromegaly
Interventions
PasireotideDrug
* Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or * Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks
octreotide LAR 30mgDrug
In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
lanreotide ATG 120mgDrug
In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With a Reduction of Mean GH Levels to < 2.5 µg/L and Normalization of Sex- and Age-adjusted IGF-1.Time frame: At 24 weeks
Locations
60 sites in 18 countries. Site status is shown where the registry gives one.
University of Michigan
Ann Arbor, Michigan
Oregon Health & Science University
Portland, Oregon
University of Texas Southwestern Medical Center Division of Hematology/Oncolog
Dallas, Texas
Swedish Neuroscience Institute 550 17th Avenue, Suite 500
Seattle, Washington
Novartis Investigative Site
CABA, Buenos Aires, Argentina
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Edegem, Antwerpen, Belgium
Novartis Investigative Site
Fortaleza, Ceará, Brazil
Novartis Investigative Site
São Luís, Maranhão, Brazil
Novartis Investigative Site
Rio de Janeiro, Rio de Janeiro, Brazil
Novartis Investigative Site
Joinville, Santa Catarina, Brazil
Novartis Investigative Site
Botucatu, São Paulo, Brazil
Novartis Investigative Site
Campinas, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
São Paulo, São Paulo, Brazil
Novartis Investigative Site
Sherbrooke, Quebec, Canada
Novartis Investigative Site
Bogotá, Colombia
Novartis Investigative Site
Cali, Colombia
Novartis Investigative Site
Bogota, Cundinamarca, Colombia
Novartis Investigative Site
Dijon, France
Novartis Investigative Site
Le Kremlin-Bicêtre, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Saint Herblain - Nantes, France
Novartis Investigative Site
Bron, Cedex, France
Novartis Investigative Site
Toulouse, Cedex 9, France
Novartis Investigative Site
Erlangen, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
München, Germany
Novartis Investigative Site
Würzburg, Germany
Novartis Investigative Site
Petah Tikva, Israel
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Genova, GE, Italy
Novartis Investigative Site
Messina, ME, Italy
Novartis Investigative Site
Roma, RM, Italy
Showing 40 of 60 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.